blue-8k_20180620.htm

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 20, 2018

 

bluebird bio, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

DELAWARE

001-35966

13-3680878

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

 

 

 

60 Binney Street,

Cambridge, MA  

 

02142

(Address of Principal Executive Offices)

 

(Zip Code)

Registrant’s Telephone Number, Including Area Code: (339) 499-9300

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 


Item 5.07

Submission of Matters to a Vote of Security Holders

 

On June 20, 2018, bluebird bio, Inc. (the “Company”) held its previously announced Annual Meeting of Stockholders (the “Meeting”), at which a quorum was present.  At the Meeting, the stockholders of the Company voted on the three proposals as follows: (i) John O. Agwunobi, Mary Lynne Hedley and Daniel S. Lynch as Class II members of the Board to serve until the Company’s 2021 annual meeting of stockholders (“Proposal 1”); (ii) to approve, on a non-binding advisory basis, the compensation paid to our named executive officers (“Proposal 2”); and (iii) to ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2018 (“Proposal 3”).

 

The Company’s stockholders re-elected the three persons listed below as Class II directors pursuant to Proposal 1. The voting results were as follows:

 

 

Votes For

Votes Against

Abstentions

Broker Non-Votes

John O. Agwunobi

43,355,149

124,989

56,738

3,617,795

Mary Lynne Hedley

43,470,010

11,058

55,808

3,617,795

Daniel S. Lynch

43,217,635

259,405

59,836

3,617,795

 

The Company’s stockholders approved Proposal 2 in a non-binding advisory vote.  The voting results were as follows:

 

Votes For

Votes Against

Abstentions

Broker Non-Votes

42,966,803

529,966

40,107

3,617,795

 

The Company’s stockholders approved Proposal 3.  The voting results were as follows:

 

Votes For

Votes Against

Abstentions

Broker Non-Votes

47,004,673

80,090

69,908

0

 


 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

 

 

Date: June 21, 2018

bluebird bio, Inc.


 

 

 

By:

/s/ Jason F. Cole

 

 

 

Jason F. Cole

 

 

 

Chief Legal Officer